In vitro inhibition of STAT3 phosphorylation in psoriasis, Crohn's and SLE patients.

Completed

• Conditions: chronic inflammatory disorders; 10017969; 10003816; 10014982

• Registration Number: NL-OMON35388
• Lead Sponsor: TNO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use local corticosteroids or ointments to prevent dry skin
Crohn's: Adults (m/f) diagnosed with Crohn's disease. Patient must have experienced active disease in two years.
SLE: Adults (m/f) in remission or mild flare SLEDAI<5 .

Exclusion Criteria

Psoriasis and Crohn's disease: patients have not received systemic treatment in last 2 months(methotrexate,cyclosporin A, corticosteroids, anti-TNF treatments) and no NSAIDS , iin last 6hours.
SLE: Patients have a SLEDAI <5. patients have not received systemic treatment in last 2 months(methotrexate,cyclosporin A, corticosteroids, anti-TNF treatments) and no NSAIDS , iin last 6hours.;Gender or age of the adults are not exclusion criteria (see Appendix 2).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Measurement of STAT3 phosphylation in different in vitro conditions in human<br /><br>blood. Mainly by Facs analysis.<br /><br>- Inhibition of the phosphorylation by various test compounds.<br /><br>- Measurement of IL-23 in serum of patients.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Expression of inflammatory mediators and surface markers in blood cells after<br /><br>and during pSTAT3 phosphorylation.</p><br>